The role of angiotensinconverting enzyme inhibitors in the treatment of hypertension

Current Cardiology Reports

Volumn 3, Issue 6, 2001, Pages 511-518

  Sleight, Peter ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CLINICAL TRIALS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RANDOMIZED CONTROLLED TRIALS;

EID: 0035514237     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0074-1     Document Type: Article

References (22)

1. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998, 317:713-720.
2. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
3. Blood Pressure Lowering Treatment Trialist's Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 355:1955-1964.
4. Furberg CF, Psaty BM and Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331.
5. Pahor M, Kritchevsky SB, Zuccala G, et al.: Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998, 21:193-194.
6. Hansson L, Lindholm L, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
7. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
8. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
9. Beevers DG, Sleight P: Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: Is there a risk? Br Med J 1996, 312:1143-1145.
10. Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta analysis of 109 treatment studies. Am J Hypertens 1992, 5:95-110.
11. Fagard RF, Stassen JA, Thijs L: Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. J Hypertens 1997, 15:1493-1502.
12. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin- converting- enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
13. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
14. Hansson L, Lindholm L, Niskanen L, et al.: Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999, 353:611-616.
15. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765-774.
16. Mann JFE, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE Randomized Trial. Ann Intern Med 2001, 134:629-636.
17. Davies MJ: Reactive oxygen species, metalloproteinases, and plaque stability. Circulation 1998, 92:2382-2383.
18. Lonn E, Yusuf S, Dzavik V, et al., for the SECURE Investigators: Effects of ramipril and of vitamin E on atherosclerosis: results of the prospective, randomised Study to Evaluate carotid Ultrasound Changes in patients treated with Ramipril and Vitamin E (SECURE). Circulation 2001, 103:919-925.
19. Mathew J, Sleight P, Lonn E, et al.: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor, Ramipril. Circulation 2001, in press.
20. Williams B: The renin angiotensin system and cardiovascular disease: hope or hype? JRAAS 2000, 1:142-146.
21. Stratton IM, Adler AI, Neil AW, et al., on behalf of the UK prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. Br Med J 2000, 321:405-412.
22. Yusuf S, Peto R, Lewis J, et al.: Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985, 27:335-371.